CSF1R and central nervous system cancer: In a glioma mouse model, a tyrosine kinase inhibitor PLX3397 that targets CSF-1R, c-Kit and Flt3 blocks tumor progression through depolarizing M2 phenotype of TAMs and impairing their pro-tumor function [175].